Full-Time

Endocrine Account Manager

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$155k - $210k/yr

+ Bonus + Equity

Cincinnati, OH, USA

In Person

Hybrid work model; field-based in Cincinnati; significant travel.

Category
Sales & Account Management
Required Skills
Sales
Data Analysis

Get referred to BridgeBio

Find people who can refer or advise you

Requirements
  • 8-10 years of successful experience in the pharmaceutical industry and 4+ years in Endocrine Disease and/or Nephrology required.
  • BS/BA Required, MBA Preferred but not required
  • Product/indication launch experience: Track record of successfully launching new products and/or new indications into highly competitive and/or new markets
  • Strong leadership, planning and organization, analytics, business acumen, decision making and problem- solving skills
  • Ability to prioritize and execute on plan
  • Proven leadership skills with a history of holding oneself to a high level of accountability
  • Ability to influence without authority, internally as well as externally
  • Excellent written and oral communication skills
  • Excellent skills in using remote technology and AI to engage with customers and analyze business opportunities.
  • Adherence to BridgeBio’s high ethical standards
  • Large geographies. Significant travel will be required
Responsibilities
  • Meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets.
  • Will demonstrate subject matter expertise concerning scientific and clinical information for Encaleret.
  • Will take a customer-centric approach and engage customers in clinically relevant discussions utilizing approved materials.
  • Will effectively analyze sales and targeting data to identify opportunities for business growth or areas of concern in their territory.
  • Be responsible for territory business planning and execution of key company initiatives
  • Will adhere to company guidelines and demonstrate honesty, integrity, trust, respect, and accountability and perform all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations
  • Will exhibit compliant partnership with Medical Science Liaisons, Field Reimbursement, Patient Access, HUB and other key cross-functional team members to develop strategies to ensure a high level of customer satisfaction
  • Develop and implement a dynamic territory business plan by analyzing the ADH1 market in their territory to drive business. Develops, nurtures and maintains professional relationships with targeted HCP’s including physicians, medical staff, and key personnel and multi-disciplinary staff
  • Anticipates potential business challenges, adjusts priorities as needed, demonstrates flexibility, and develops solutions to address challenges
  • Maintains an exceptional level of proficiency in selling skills, clinical, market and product knowledge and the business environment of the territory.
  • Collaborates with peers and company personnel to ensure corporate objectives and initiatives are achieved.
  • Effectively plans and organizes schedule to ensure maximum efficiency and use of time to accomplish goals and objectives
  • Acts as an ambassador on behalf of BridgeBio. Present a professional image and represent the company, products and people with integrity and respect.
  • Ensures that all activities are following applicable regulations, compliance and Pharma guidelines
Desired Qualifications
  • Rare disease experience is highly preferred

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Get referred to BridgeBio

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby generated $362.4 million US sales in 2025 following AstraZeneca's Wainua trial failure.
  • Three Phase III readouts for encaleret, infigratinib, and BBP-418 expected in fall 2025 to early 2026.
  • Global ATTR therapy market opportunity exceeds $20 billion with DKSH partnership expanding Asia Pacific access.

What critics are saying

  • Rinascera Therapeutics launched July 2026 with RIN-002, directly eroding BridgeBio's potential dermatology franchise revenue.
  • Operating margin of -87% and 93% revenue reliance on Attruby creates existential vulnerability before pipeline inflection.
  • $750 million credit facility increases leverage risk if Phase 3 readouts for encaleret or BBP-418 delay beyond 2026.

What makes BridgeBio unique

  • Decentralized hub-and-spoke model creates autonomous subsidiaries for specific genetic diseases.
  • Focuses exclusively on Mendelian diseases with well-understood single-gene genetic drivers.
  • Rapid capital reallocation and data-driven decision-making across 15+ drug programs simultaneously.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

3%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.